第30回日本乳癌学会学術総会 第30回日本乳癌学会学術総会

Call for Abstracts

Abstract Submission Period

October 18 (Mon), 2021 – December 21 (Tue), 2021
January 14 (Fri), 2022（JST）
We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.

Abstract Submission Guideline

Abstract Title Limited to 100 characters
Abstract Body Without a Figure / Table
Limited to 2,000 characters

With a Figure / Table
Limited to 1,400 characters*
Total number of Authors Up to 20 authors
Total number of Affiliations Up to 10 affiliations


The submitted abstract must describe unpublished work.
Please do not submit multiple copies of the same abstract.
Late abstract submission will not be accepted.

Presentation Style

Abstracts can be accepted as Oral / Poster presentation.

Oral presentation

Abstracts with Innovative Approach will be selected as the Excellent Oral Presentations.

Poster presentation

  1. Poster Discussion
    There will be discussions with moderators on excellent poster presentations.
  2. Mini Poster Presentation
    You register your presentation slides in advance and present it.
  3. e-Poster
    There will be no presentations or Q&As.
    Attendees can view the e-Poster.
    There will be no poster viewing at the venue.

Categories

Please select a category for your presentation from Categories and submit your abstract.
The Program Committee will make the final decision on the presentation categories.

CategoryField
Basic ScienceA-01Genomics
A-02Epigenetics
A-03Oncogenes/Tumor Suppressor Genes
A-04Hormone/Hormone Receptor
A-05Proteomics
A-06Cell Cycle/DNA Damage and Repair
A-07Transcriptional Regulation and Signal Transduction
A-08Drug Resistance
A-09Cancer Stem Cells
A-10Epithelial-Mesenchymal Transition
A-11Invasion, Metastasis
A-12Microenvironment/Angiogenesis
A-13Tumor Immunology
A-14micro RNA
A-15New Drugs/Drug Delivery System
A-16Others (Basic Science)
Screening and PreventionB-01Screening Mammography
B-02Screening Ultrasound
B-03Improvement of Screening rate, Promotion activities
B-04Screening MRI
B-05Screening by liquid
B-06Secondary Examination (Detailed Examination)
B-07Prevention
B-08Screening under the Circumstance of COVID-19
B-09Others (Screening/Prevention)
Diagnostic ImagingC-01Mammography
C-02Ultrasonography
C-03MRI
C-04CT/PET-CT
C-05New Imaging modality
C-06Others (Diagnostic Imaging)
Pathological DiagnosisD-01Benign Tumor
D-02Borderline Lesions/Difficult to Distinguish Lesions
D-03Non-invasive Cancer
D-04Invasive Cancer
D-05Special Type
D-06Paget's Disease
D-07Non-epithelial or Unclassifiable Tumors
D-08Assessment of Surgical Margin
D-09Sentinel Lymph Node Diagnosis
D-10OSNA/Intraoperative Diagnosis
D-11Therapeutic Effect of Preoperative Systemic Therapy
D-12Primary and Metastatic Lesions
D-13ER/PgR/HER2/Ki67/PD-L1 testing
D-14Cytology
D-15Molecular Imaging
D-16Others (Pathological Diagnosis)
InterventionE-01Fine Needle Aspiration Cytology
E-02CNB/VAB
E-03US-guided biopsy
E-04Stereotactic biopsy
E-05Others (Intervention)
BiomarkerF-01Prognostic Factor
F-02Predictive Factor
F-03Others (Biomarker)
Multi gene panel/Liquid biopsyG-01Gene Panel Testing
G-02Liquid Biopsy
G-03Others (Gene Panel / Liquid Biopsy)
Social Health MedicineH-01Medical Epidemiology, Social Epidemiology
H-02Genetic Medical Research
H-03Health Economics
H-04Health Informatics, Preventive Medicine　
Medical CommunicationI-01Medical Communication
I-02Wearable Device
I-03Online Medical Care
Women's HealthJ-01Risk Factor, Prevention
J-02Bone Health
J-03Preservation of Fertility
Hereditary Breast CancerK-01Genetic Testing
K-02Genetic Counseling
K-03Biology, Clinico-Pathological Feature
K-04Surveillance, Risk reduction surgery
K-05Approach to the Family Member
K-06Others (Treatment of Hereditary Breast Cancer)
Surgical TreatmentL-01Sentinel Lymph Node Biopsy
L-02Preoperative Systemic Therapy and Sentinel Lymph Node Biopsy
L-03Breast-conserving Surgery
L-04Surgical Treatment for Ipsilateral Breast Tumor Recurrence
L-05Minimally Invasive Surgical Treatment
L-06Non-surgical Ablation
L-07Breast-conserving Surgery and Cosmesis
L-08Surgical Treatment for Locoregional Recurrence
L-09Surgical Treatment for Distant Metastatic Lesions
L-10Postoperative Surveillance
L-11Perioperative Nursing
L-12Medical Equipment
L-13Others (Surgical Treatment)
Oncoplastic Surgery / Breast ReconstructionM-01Oncoplastic Surgery
M-02Breast Reconstruction
Radiation TherapyN-01Radiation Therapy after Breast Conserving Therapy
N-02Postmastectomy Radiation Therapy
N-03Adverse Events due to Radiation Therapy
N-04New Radiation Therapy Technology, Method, Equipment
N-05Radiation Therapy for Metastasis/Recurrence
N-06Radiation Therapy Nursing
N-07Others (Radiation Therapy)
Systemic Therapy (Preoperative, Postoperative)O-01Preoperative Hormone Therapy
O-02Preoperative Chemotherapy
O-03Preoperative Molecular Targeted Therapy
O-04Postoperative Hormone Therapy
O-05Postoperative Chemotherapy
O-06Postoperative Molecular Targeted Therapy
O-07Immune Checkpoint inhibitors
O-08Hormone Receptor Positive
O-09HER2 Positive
O-10Triple Negative
O-11New Drug
O-12Others (Systemic Therapy, Pre- and Postoperative)
Systemic Therapy (Metastasis, Recurrence)P-01Hormone Therapy
P-02Chemotherapy
P-03Molecular Targeted Therapy
P-04Immune Checkpoint Inhibitors
P-05Hormone Receptor Positive
P-06HER2 Positive
P-07Triple Negative
P-08New Drug
P-09Others (Systemic Therapy, Metastasis and Recurrence)
Clinical TrialsQ-01Clinical Trials (Systemic Therapy)
Q-02Clinical Trials (except Systemic Therapy)　
Q-03Clinical Trials Currently in Progress
Medication Management, Guidance, Safety ManagementR-01Medication Management, Guidance
R-02Safety Management
R-03Others (Medication Management, Guidance, Safety Management )
Team Medicine/Medical CooperationS-01Satisfaction of Patients, Families, and Medical staff
S-02Supportive Care
S-03Lymphedema
S-04The Role of Pharmacists
S-05The Role of Nurses
S-06Medical IT
S-07Medical Cooperation
S-08Others (Team Medicine/Medical Cooperation)
Medical Treatment for Specific Patients and PathophysiologyT-01Juvenile Breast Cancer
T-02Elderly Breast Cancer
T-03Male Breast Cancer
T-04Bilateral Breast Cancer
T-05Special Histopathological Type
T-06Inflammatory Breast Cancer
T-07Locally Advanced Breast Cancer
T-08Occult Breast Cancer
T-09Treatment of Breast Cancer Patients with Comorbidity
T-10Others (Medical Treatment for Specific Patients and Pathophysiology)
Palliative MedicineU-01Symptom Relief
U-02Psychological Support
U-03Social support, QOL Improvement
U-04Others (Palliative Medicine)
SurvivorshipV-01Survivorship
Psychological and Social SupportW-01Psycho-oncology
W-02Advanced Care Planning
W-03Patient Support Activities, Patient Groups, Family Support
W-04Others (Psychological and Social Support)
Big DataX-01Image Information, Pathological Information
X-02Others (Big Data)
Artificial IntelligenceY-01Omics Data
Y-02Clinical Application (Diagnosis)
Y-03Others (Artificial Intelligence)
Breast Cancer Treatment Under COVID-19Z-01Breast Cancer Treatment Triage
Z-02Breast Cancer Treatment for COVID-19 Patients
Z-03Preventing Infection, Patient Support
Z-04Others (Breast Cancer Treatment Under COVID-19)
Lifestyle/Work Style/EducationAA-01A New Way of Living and Working with COVID-19
AA-02Work Style Reform, Task Shift
AA-03Education, Human Resources Development
AA-04Others (Lifestyle/Work Style/Education)
Case ReportAB-01Diagnosis (Pathology, Images, etc.)
AB-02Surgical Treatment
AB-03Drug Therapy
AB-04Radiation Therapy
AB-05Palliative Medicine
AB-06Clinical Course/Pathology
AB-07Nursing
AB-08Others (Case Report)

Presentation Data

Your presentation data will be released on our website for around 3 months after the Meeting.
Please select if you agree with it.
In case your abstract is accepted as the e-Poster and do not agree with it, your abstract will be withdrawn.
In case your abstract is selected as other than the e-Poster and you do not agree with it, your abstract might be withdrawn depending on session.

Conflict of Interest Disclosure

The author is required to report applicable COI (Conflict of Interest) in the past three years by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process. Please check the details here.

Notification

We will send a notification by email around April in 2022.

Hybrid Meeting

The 30th JBCS will be held as a Hybrid Meeting (Onsite & Online).
We will inform you of more details later.

Travel Grant

The 30th JBCS organizing committee encourages breast care specialists in other countries and regions to submit abstracts for oral / poster presentations.
After confirming the guidelines below, please submit your abstract.
All submitted abstracts are eligible for the travel grant application.

To applicants

  1. Breast care specialists who apply from countries and regions other than Japan are eligible.
  2. An applicant must be the first author and presenter of the submitted abstract.
  3. Travel grant will be provided for the awardees after their presentations onsite.
  4. Please note that complimentary accommodation will not be offered, and all arrangements for the applicant’s transportation to the venue and accommodation during the congress period will be the applicant’s responsibility.
  5. Result of the review will be announced in acceptance notifications sent by e-mail in the end of April, 2022.
  6. There is no age limitation.

Abstract Submission

Contact

The 30th Annual Meeting of the Japanese Breast Cancer Society
Congress Secretariat
Japan Convention Services, Inc.
program-30jbcs@convention.co.jp